Opioid Agonist vs. Antagonist: Comparing How They Work

This article is general information for educating the reader. It is not medical advice.

Understanding the differences between an opioid agonist and antagonist can help you understand the various treatments available for opioid use disorder.

A Brief Overview of Opioid Receptors

Opioid receptors are proteins located throughout the central nervous system (CNS), that is the brain and spinal cord, and throughout the body. Depending on how stimulated they are, they can inhibit pain, modify emotional responses to stimuli, and affect breathing. [1] The manner in which a drug stimulates these receptors determines its clinical purpose such as pain relief or reversing a potentially life-threatening overdose.

There are three types of opioid receptors:

• Mu
• Kappa
• Delta

Of these three, mu receptors are the most relevant because they are responsible for providing the greatest amount of pain relief and the euphoric response produced by opioids. Kappa receptors provide some degree of pain relief but typically result in dysphoria (a feeling of unease) when stimulated. Delta receptors also affect mood and pain perception.

How a drug affects these receptors determines whether it is a full agonist, partial agonist, or antagonist. This distinction shapes everything from pain-relieving effectiveness to overdose risk.

Full Opioid Agonists: Maximum Activation

Full opioid agonists bind to mu opioid receptors and fully activate them. This means full activation of mu receptors generates analgesia (pain relief) and euphoria. However, full activation of mu receptors also increases the risk of adverse effects such as respiratory depression, sedation, dependence, an increased likelihood of misuse, and addiction.

Examples of full agonists include morphine, fentanyl, oxycodone, hydrocodone, methadone, and heroin. Morphine, fentanyl, oxycodone, hydrocodone, and methadone are used to treat pain and induce surgical anesthesia. Heroin is an illicit opioid with no accepted medical use in the US.

Methadone is also used for medication-assisted treatment (MAT) for opioid use disorder. It helps patients by reducing withdrawal symptoms and cravings. [2]

Partial Opioid Agonists

Partial opioid agonists bind to opioid receptors but activate them only partially, even at the highest doses. This ceiling effect makes them significantly less likely to cause an overdose than full agonists, since higher doses do not continue to increase respiratory depression or sedation. [3]

Buprenorphine is an example of a partial agonist that is frequently used in addiction medicine. [4] It is a partial agonist at mu receptors and an antagonist at kappa receptors. Although still highly potent, it has a ceiling effect that significantly reduces overdose risk. Buprenorphine also binds so tightly to opioid receptors that it can displace full agonists already attached, acting as a blocker in the presence of other opioids.

Due to buprenorphine’s ceiling effect and ability to displace full agonists, it has been approved as a component of MAT for individuals suffering from substance use disorder involving opioids. It is available in two forms: Subutex (buprenorphine alone) and Suboxone (buprenorphine combined with naloxone). Additional partial agonist examples include tramadol and butorphanol; however, buprenorphine is the accepted option for addiction treatment.

Mixed Agonist/Antagonist: Acting on Multiple Receptors

In addition to being an agonist at one receptor type and antagonist at another, there are opioids that possess both characteristics.

Both nalbuphine and pentazocine act as kappa agonists while inhibiting activity at mu receptors. [5] Like all opioids, they generate some level of pain relief. However, unlike most opioids, they can produce dysphoric responses in individuals who take them. Moreover, both nalbuphine and pentazocine can precipitate withdrawal in individuals who are addicted to or have developed tolerance to full agonists. [6]  Their use is limited in modern clinical practice for these reasons.

Opioid Antagonist Drugs: Blocking Without Activation

Opioid antagonist drugs attach to opioid receptors but do not activate them. Through occupation of opioid receptors, these drugs can prevent agonists from attaching to their sites of action, resulting in a reversal or neutralization of side effects caused by opioids such as respiratory depression, sedation, or euphoria. This opioid antagonist mechanism of action makes them essential in overdoses and useful for long-term treatment. [7]

Opioid antagonists include:

• Naloxone (Narcan): A fast-acting antagonist that works within minutes when administered intravenously or as nasal spray, displacing opioids from their receptor sites and restoring breathing during an overdose. Since naloxone has a relatively shorter duration than most opioids, repeated administration may be necessary for an overdose, and ongoing emergency management is necessary.
• Naltrexone (Vivitrol): A long-lasting antagonist used after medical detoxification to support relapse prevention. Naltrexone prevents the euphoric effects caused by opioids. It is available as both a daily pill and monthly extended-release injections.
• Nalmefene: A long-acting antagonist with select applications in overdose management and relapse prevention.
• Peripheral Acting Mu-Opioid Receptor Antagonists (PAMORAS): Drugs like methylnaltrexone and alvimopan target opioid receptors localized outside of the CNS to relieve opioid induced constipation without inhibiting pain relief.

Suboxone combines buprenorphine with naloxone specifically to deter misuse of the buprenorphine alone. If the user injects the drug trying to get high, the naloxone activates, triggers withdrawal, and blocks any euphoric effect.

Why These Differences Matter in Addiction Treatment

One common misconception about MAT is that it substitutes one addiction for another.

This is not true. Using methadone or buprenorphine under supervision in a professional setting is very different from abusing opioids. Both medications stabilize patients at consistent doses, preventing withdrawal and inhibiting cravings without producing the rewards or dangers of misuse. MAT can significantly reduce the number of overdose deaths, lowers disease transmission risk, and improve long-term success rates for recovery. [8]

Antagonists (naltrexone) serve a different purpose in treatment. They are more often used by people who have detoxed and need a medication that will block opioid rewards.

MAT does not replace psychotherapies such as cognitive behavioral therapy or dialectical behavior therapy. The combination of MAT with appropriate psychotherapy or counseling supports favorable recovery outcomes more effectively than either approach used by itself.

If you or someone you know is considering seeking assistance for opioid abuse, we are here to help. Alpas provides evidence-based substance abuse treatment and supportive therapeutic services for adults experiencing addiction disorders. Our multidisciplinary team is here to support your journey every step of the way. Recovery is possible.